Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2025-08-14 00:00:00 ET · period of report 2025-08-12 · accession 0001714899-25-000176 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-14 | 2025-08-12+ | DNLI | Ho Carole | Chief Medical Off | S - Sale | $13.81 | -3,743 | 217.4K | -2% | -$51.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-13 | S | D | 806 | $14.64 | 216,585 | D | — | — | (F3) Includes 128,405 Unvested RSUs. |
| 2 | Common | Common Stock | 2025-08-12 | S | D | 2,937 | $13.58 | 217,391 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 128,405 Unvested RSUs. |